Regeneron, Sanofi Expand Alliance With $1B Upfront, Up To $7B Milestones
Regeneron Pharmaceuticals (REGN) has expanded its antibody collaboration with Sanofi, adding four long-acting immunology antibodies. Regeneron will receive $1 billion upfront and could receive up to $7 billion in milestones. The companies will share costs and split future profits 50:50 globally.
Regeneron expanded its antibody collaboration with Sanofi by adding four long-acting immunology antibodies. Regeneron will receive $1B upfront and may receive up to $7B in milestones, while the companies will share costs and split future profits 50:50 globally.